PCN126 Can a Population-Based Patient Registry Improve the Feasibility of Outcomes Research in Multiple Myeloma?  by Blommestein, H. et al.
RESULTS: The responses from 29 of the thirty-two patients (91%) surveyed were
analyzed. Most patients were able to answer questions regarding FN, including
whether their health care provider had discussed, and if they had received, any FN
prophylaxis (81% and 60%, respectively). The attribute with the most impact on
patient’s choices was “risk of developing an infection”; whereas “inconvenience of
treatment” had the least impact and was likely confounded with “frequency of
treatment.” The median completion time was 13 minutes. CONCLUSIONS: The
pilot study results suggest that the survey is feasible in the breast cancer popula-
tion. The only change to the survey instrument will be the removal of the attribute
“inconvenience of treatment”; otherwise, the 16 treatment-scenario design, in-
cluding the “no treatment” option, will be maintained.
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OBJECTIVES: Metastatic breast cancer (MBC) patients are treated with a variety of
regimens with differing side effects that can reduce the patients’ quality of life.
Conjoint analysis is a research method used to evaluate how trade-offs are made
between different attributes. This study assessed the willingness to pay (WTP) to
avoid side effects related to MBC treatment using conjoint analysis. METHODS: An
online, self-administered conjoint analysis survey of US adult female MBC patients
was conducted to elicit preferences for MBC treatment side effects. Attributes in-
cluded in the analysis with levels described in lay terms were: Alopecia, Diarrhea,
Fatigue, Nausea, Neuropathy, Pain, Neutropenia and Out of pocket costs. 15 choice-
based conjoint questions were presented where patients selected the most pre-
ferred therapy. A partial profile design was used to allow for each treatment de-
scription to be made with 3 instead of all 8 attributes. The attribute choices for each
question included two side effects and an out of pocket price. The survey also
collected information on prior treatment regimens, previous side effect history,
and demographics. RESULTS: There were 298 respondents. Most respondents were
white (84%), married (57%) over 40 years of age (86%), and covered with private
insurance (57%). MBC patients were WTP (US$) $3,894 to avoid severe diarrhea,
$3,479 to avoid being hospitalized due to infection, $3,211 to avoid severe nausea,
$2,764 to avoid severe tingling in hands and feet, $2,652 to avoid severe fatigue,
$1,853 to avoid obvious hair loss and $1,458 to avoid severe pain. The most impor-
tant attributes when selecting a therapy for MBC in terms of average utility were
neutropenia, diarrhea and nausea. CONCLUSIONS: Patients most highly value the
avoidance of diarrhea, neutropenia, and nausea with MBC treatment regimens.
Additional research with a global patient population is needed to quantify the WTP
to avoid MBC side effects.
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OBJECTIVES: Cancer more than other diseases concerns not only patients them-
selves, but also close relatives of patients. The aim of this study was to estimate lost
productivity in a population of close relatives of cancer patients who provide them
with home care. METHODS: Survey on a representative sample of Polish econom-
ically active population of close relatives to cancer patients was planned. To assess
the impact of cancer on productivity of relatives to cancer patients a modified
questionnaire WPAI-SHP was used. The WHO performance scale was used to as-
sess general health status of cancer patients. Human capital approach was used to
estimate the absenteeism and presenteeism costs. Values are presented in Euro
(exchange rate: 1 EUR4.20 PLN). RESULTS: A total of 23,518 persons were ques-
tioned between August 2011 and April 2012. Of them 112 (0.48%) met inclusion
criteria and completed WPAI-SHP questionnaire but only 98 persons completed
questionnaire properly and were finally included in calculation. The mean age of
included persons was 40.212.5 years and the average declared weekly work time
was 42.714.1 hours. The average percent work time missed due to close relatives
cancer was 4.7% and corresponded to a weekly average time of the absence of 1.9
hours. In contrast, the percent of working impairment due to cancer of close rela-
tives was estimated at 21.0% and corresponded to weekly average productivity loss
of 7.3 hours. When projected on total population, the estimated indirect costs
associated with absenteeism amounted to about 154.5 million EUR and were sig-
nificantly lower than the estimated costs of presenteeism – 607.4 million EUR.
CONCLUSIONS: The analysis showed that the loss of productivity in a population
of close relatives of cancer patients have important implications for the Polish
economy, however less pronounced than costs of productivity loss measured in
cancer population (1,935 billion EUR).
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OBJECTIVES: We previously reported that indirect costs of absenteeism in the
workplace owing to cancer are almost twice as high as the estimated direct costs of
cancer treatment in Poland. Although approximately 60% of the absenteeism costs
were caused by premature mortality, to gain a full understanding of the indirect
costs of lost productivity the presenteeism in the workplace must be analyzed.
METHODS: Survey on a population of about 300 economically active patients (score
80 or above on Karnofsky performance scale) with cancer was planned at 10 re-
gional oncology centers in Poland. To assess the impact of health on productivity a
modified questionnaire WPAI-SHP was used. Due to the considerable heterogene-
ity of the study group and given the limited number of respondents we have re-
frained from collecting data on clinical characteristics of the disease. Human cap-
ital approach was used to estimate the presenteeism costs. Values are presented in
Euro (exchange rate: 1 EUR4.20 PLN). RESULTS: Data on 299 patients were col-
lected. The mean age of surveyed patients was 51 years and the average declared
weekly work time was 41 hours. The average time of the absence from work due to
cancer in the study population was 7.69.9 hours. The estimated average loss of
productivity in the workplace was 37.3%, corresponding to 10.38.5 loss of hours of
work. When projected on total economically active population with cancer, the
estimated indirect costs associated with the presenteeism amounted to about 363
million EUR and were significantly lower than the previously estimated costs of
sickness absence (1,572 million EUR).CONCLUSIONS:The analysis showed that the
loss of productivity associated with the presenteeism among cancer patients has
important implications for the Polish economy but less pronounced than costs of
absenteeism in the workplace. This study was funded by the Ministry of Science and
Higher Education grant no. N N405 115034.
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OBJECTIVES: Dutch policy requires evidence from outcomes research for the as-
sessment of appropriate drug use and real-world cost-effectiveness. We investi-
gated whether a population-based patient registry could improve the feasibility of
outcomes research in multiple myeloma compared to a retrospective cohort study.
METHODS: Two methods were used to investigate the feasibility of outcomes re-
search. First, we conducted outcomes research for bortezomib in multiple my-
eloma (n139) by retrospectively collecting detailed data from hospital medical
records in 38% of all Dutch hospitals. Second, we conducted outcomes research by
using a population-based registry for haematological malignancies (PHAROS) cov-
ering 40% of the Netherlands. Up till now, the registry contains 3093 patients,
including 802 patients with multiple myeloma. RESULTS: In the retrospective bort-
ezomib study, it was possible to gather data on drug and resource use in everyday
practice. However, due to great patient heterogeneity, extensive treatment varia-
tion (10 drugs in20 combinations) and missing prognostic information (e.g. 71%
missing serum 2-microglobulin levels), it was impossible to estimate incremental
cost-effectiveness of bortezomib. The PHAROS population-based registry also pro-
vided data on drug and resource use in everyday practice. Like the retrospective
study, the registry revealed extensive treatment variation. This, in combination
with great patient heterogeneity, challenged the feasibility to identify appropriate
groups of comparable patients to calculate cost-effectiveness. CONCLUSIONS:
Compared to a clinical trial, outcomes research in multiple myeloma is compli-
cated by extensive treatment variation and wide patient heterogeneity. The
PHAROS registry provides better generalisable outcomes research results, but
many challenges remain in data analysis. Nevertheless, the greater number of
real-world patients might provide the opportunity to obtain a sufficiently valid
cost-effectiveness estimate by using comprehensive modeling techniques and dif-
ferent data sources.
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OBJECTIVES: Dutch policy regulations for expensive inpatient drugs require out-
comes research for the assessment of appropriate drug use and cost-effectiveness
after four years of temporary reimbursement. We investigated whether outcomes
research of bortezomib in advanced multiple myeloma reduced decision makers’
uncertainty. METHODS: Our cohort study included 139 patients who were treated
for advanced multiple myeloma outside of a clinical study. Detailed data were
retrospectively collected from medical records in 38% of all Dutch hospitals.
RESULTS: It was possible to develop evidence on types of drug used, dosages, dose
modifications and health care costs. However, it was impossible to identify a single
treatment comparator (10 drugs in 20 combinations), partly due to rapid devel-
opments in treatment for multiple myeloma. Moreover, patients treated with bort-
ezomib (n72) were not comparable to other patients (n67) regarding prognostic
factors. It was not clear whether physicians used standardised outcome measures
(i.e. EBMT response and CTC toxicity criteria) since such information was often not
reported in medical records. Although different adjustment techniques were ap-
plied to the Cox multivariate regression model to obtain a valid (overall) survival
estimate, none succeeded in correcting for the observed confounding. Moreover,
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